In honor of the Grand Opening of JLABS @ NYC, Johnson & Johnson Innovation has launched a QuickFire Challenge to award up to four new game-changing early-stage innovation companies with the use of a bench, workstation and access to the JLABS @ NYC community for one year.
Rewards and benefits
Areas of interest
This competition will award the person or team(s) who submits the best idea, technology, or solution in the following areas:
- Consumer healthcare
- Health technologies
- Medical devices
Frequently Asked Questions
Make sure your browser is up to date and accepting cookies. You can contact customer service at https://jnjawards.fluidreview.com/helpdesk/contact/ if you are having technical difficulties as well.
For challenges involving space at JLABS, that entails 1 lab bench and 1 workstation (desk) for 2 people maximum. If you have more employees we can rent out an additional space.
Each applicant will be required to submit to a background check, which is subject to a minimal fee. We also collect a deposit that is refundable at the end of the lease term. There may be other expenses, but this will be dependent on the work that the company is doing in JLABS. There may also be fees associated with EH&S waste, specialty equipment, printing and phone calls.
No, any additional fees and paperwork are up to the winner.
Do not submit confidential information. Only non-confidential information should be submitted and anything you submit will be treated as non-confidential.
As this is a no strings attached arrangement, JLABS does not acquire any IP. Any IP creation and/or protection remains the sole responsibility of the inventors.
No, a patent is not required to apply. However, you should not submit any information that you wish to keep confidential or that may negatively impact upon the future patentability of your invention.
We encourage all to apply. Find out more about what areas we desire to explore here: https://www.jnjinnovation.com/partnering.
Each Challenge has it’s own terms & conditions that can be found prior to filling out the application.
Please contact [email protected] with any questions.
You can setup an account at http:// jnjawards.fluidreview.com. You are able to save your work and log back in to finish at a later time if needed.
About Johnson & Johnson Innovation
Johnson & Johnson Innovation focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson’s global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers, Johnson & Johnson Innovation | JLABS, Johnson & Johnson Innovation - JLINX, Johnson & Johnson Innovation – JJDC and our Business Development teams to create customized deals and novel 4 collaborations that speed development of innovations to solve unmet needs in patients. For more information, visit www.jnjinnovation.com or follow @JNJInnovation.
About Johnson & Johnson Innovation, JLABS
Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow. At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries. JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property. JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and digital health sectors.
JLABS currently has nine locations in innovation hot spots across North America and produces entrepreneurial programs and campaigns to seek out the best science, like the QuickFire Challenges around the globe. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then, has established two locations in San Francisco - one through a collaboration with the California Institute for Quantitative Biosciences (QB3) and a second standalone facility in South San Francisco. JLABS is also located in Boston through a collaboration with LabCentral, in Lowell, Massachusetts through a collaboration with UMass, in Houston through a collaboration with the Texas Medical Center (TMC), in Toronto through a collaboration with the Ontario Government and the University of Toronto and a new JLABS @ NYC (in collaboration with the New York Genome Center -opening in 2018). For more information about JLABS, please visit www.jlabs.jnjinnovation.com.
Lab11 Therapeutics LLC: Lab11 Therapeutics LLC is a startup biotech company spun out of the Icahn School of Medicine at Mount Sinai. The company is developing host-targeting small molecule broad spectrum anti-viral drugs, with the first indication being anti-influenza A virus (IAV) drugs.
Manhattan Biosolutions: Manhattan BioSolutions is a biotech start-up focused on the discovery and development of the next-generation immunotherapy for the treatment or potential prevention of cancer. Their proprietary technology platforms are aimed to enhance or augment the natural ability of the immune system to recognize cancer as foreign and defend the body against malignancies.
Sapience Therapeutics, Inc.: Sapience Therapeutics is a preclinical-stage biotechnology company seeking to develop novel treatment approaches for oncology indications with high unmet need. Their initial goal is to develop a first-in-class treatment that targets the ATF5 transcription pathway, which holds the potential to treat many cancers, including AML, GBM, medulloblastoma, neuroblastoma, breast cancer, and more.
Mobile Sense Technologies, Inc.: Mobile Sense™ is building foundational technology that enables this transformation through off-the-chest wearables for long term management of cardiac arrhythmias. Embedded algorithms coupled with non-adhesive, wireless & waterproof sensors provide high fidelity ECG and PPG recordings.